AbCellera, Rallybio partnering on rare disease mABS

AbCellera, an antibody discovery company, is partnering with rare disease biotech Rallybio to co-develop up to five rare disease therapeutic targets.

AbCellera Biologics Inc. (NASDAQ:ABCL), which rocketed to commercial success on the back of a COVID-19 mAB it developed in tandem with Eli Lilly and Co. (NYSE:LLY), has negotiated a series of antibody discovery collaborations with biopharma companies, including EQRx Inc. and VCs, including Versant Ventures and Atlas Venture...